Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

计划入组 12 人 · 首次发布于 2024 年 10 月 16 日

Duchenne Muscular Dystrophy Heart Study

计划入组 700 人 · 首次发布于 2018 年 2 月 22 日

Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy

计划入组 42 人 · 首次发布于 2012 年 1 月 30 日

small molecule (oral, Duchenne muscular dystrophy associated cardiomyopathy)

Duchenne muscular dystrophy(Metagenomi)

MyoDys45-55(MyoGene Bio LLC)

Sarepta Therapeutics, Inc.

United States

Dyne Therapeutics

United States

Associated Capital

United States

Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Ifetroban Receives FDA Orphan Drug Designation for Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Secretome Therapeutics Secures $30 Million Series A to Advance Cardiac Cell Therapy for Duchenne Muscular Dystrophy